Biologic & Biosimilar RA Drugs Market Trends 2025–2029: Regional Outlook and Sizing Analysis
Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
How Will The Biologic & Biosimilar RA Drugs Market Valuation Change Between Now And 2029?
The market size for biologic & biosimilar ra drugs has been experiencing steady growth in recent past. The figures are set to rise further from $13.99 billion in 2024 to $14.57 billion in 2025, marking a compound annual growth rate (CAGR) of 4.1%. The growth seen in the previous periods can be traced back to factors such as the rate of market adoption, results of clinical trials, changing market shares, long-term results in patients, and pricing tactics.
Expectations are high for a robust expansion in the biologic & biosimilar ra drugs market in the coming years, with projections indicating that it will reach “$19.08 billion by 2029 at a compound annual growth rate (CAGR) of 7.0%. Factors contributing to this forecasted growth include an increase in the development of biologic drugs, competition within the market, evolving healthcare policies, patient choices, and advancements in clinical research & development. Key trends to note in this forecast period are the rise in competition in the biosimilar market, development of personalized medicine and precision therapy, enhancement of drug delivery systems and a focus on safety, efficacy and patient-centered healthcare.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp
What Are The Primary Factors Supporting The Biologic & Biosimilar RA Drugs Market Expansion?
The upward trend in the elderly demographic and the escalation in occurrences of rheumatoid arthritis are propelling the market for biologics and biosimilar RA drugs. The elderly demographic is comprised of individuals who are 60 years of age or older. Rheumatoid arthritis is an autoimmune disorder where the immune system turns on the body’s own cells, predominantly affecting the joints. This disease is more prevalent in older ages due to the immune system’s vulnerability as it weakens. Biologics and biosimilar RA drugs have proven to be a practical solution for treating rheumatoid arthritis in comparison to traditional drugs. For example, the World Health Organization (WHO), a health-focused subsidiary of the United Nations based in Switzerland, reported that approximately 1 billion individuals aged 60 and above were in the world in 2020, and this demographic is projected to escalate to 1.4 billion by 2030, and further to 2.1 billion by 2050. In addition, the Centers for Disease Control and Prevention, a public health organization operated by the US government, predicts that the number of US adults living with arthritis will rise to 78.4 million by 2040, and 34.6 million may experience limitations in activities as a result of arthritis. Consequently, the expansion of the aged population coupled with the growing incidents of RA is boosting the market for biologics and biosimilar RA drugs.
Which Segmentation Factors Are Critical In The Biologic & Biosimilar RA Drugs Market Analysis?
The biologic & biosimilar ra drugs market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches
What Are The Dominant Trends Currently Seen In The Biologic & Biosimilar RA Drugs Market?
One of the key trends in the biologic & biosimilar RA drugs market is the innovation of new treatments. Major companies are focusing on creating biosimilar treatments like Dual Concentration Biosimilar Options as affordable alternatives. In July 2023, Organon, a US-based healthcare company, and Samsung Bioepis, a biopharmaceutical company from South Korea, introduced their biosimilar of Humira (adalimumab), HADLIMA, in the US. With both high and low concentrations available, their aim is to increase accessibility and affordability for autoimmune disease patients. HADLIMA has an 85% price drop compared to Humira, thus, allowing more patients to access the treatment. The Arthritis Foundation recognizes the HADLIMA autoinjector and the patient support program, HADLIMA For You provides educational resources and co-pay support. The biosimilar is indicated for various conditions, including rheumatoid arthritis and Crohn’s disease. Available in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL), HADLIMA ensures uninterrupted care continuity for patients.
Who Are The Dominant Players In The Biologic & Biosimilar RA Drugs Market Today?
Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.
Access The Complete Report Here:
Which Region Is Likely To Register The Fastest Growth In The Biologic & Biosimilar RA Drugs Market?
North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
